INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLSPRNewsWire · 2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLSGlobeNewsWire · 4 days ago
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmGlobeNewsWire · Oct 15, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLSPRNewsWire · Oct 15, 2026
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G.GlobeNewsWire · Oct 15, 2026
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.GlobeNewsWire · Oct 14, 2026Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.26 | -$0.22 | Beat |
| May 11, 2026 | -$0.26 | -$0.18 | Beat |
| Mar 19, 2026 | -$0.20 | -$0.26 | Miss |
| Nov 7, 2025 | -$0.10 | $0.01 | Beat |
| Aug 4, 2025 | -$0.10 | -$0.24 | Miss |
| May 12, 2025 | -$0.19 | -$0.18 | Beat |